Cilta-cel found highly effective in first real-world study of patients with relapsed or refractory multiple myeloma
In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and safety results similar to those…